Brint Family Translational Research Award

Overview

Foundation Fighting Blindness

The urgent mission of the Foundation Fighting Blindness is to drive the research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. The Foundation is a beacon for those affected by these blinding diseases.

Brint Family Translational Research Program

The Brint Family Translational Research Program (BFTRP) is the Foundation’s funding initiative aimed at accelerating preclinical translational research for inherited retinal degenerations (IRD) and dry age-related macular degeneration (dAMD). The program provides funding and strategic guidance to advance novel therapies from the laboratory toward clinical application (e.g., follow-on funding, FDA investigational new drug \[IND\] filing, clinical trials, etc.). By leveraging expert mentorship in drug development, regulatory strategy, intellectual property, and commercialization engagement, the BFTRP seeks to address the complexities and diversity of these retinal diseases, increasing the number of viable treatment options for our community.

The Research Priority Areas

* Novel Medical Therapies:
* The primary goal of this research priority area is to advance the development of therapies that enhance or retain retinal function and structure by optimizing drug efficacy, improving targeted delivery, and minimizing toxicity.
* Therapeutic categories include:
* Small Molecules
* Biologics
* Alternative Therapies (research that falls outside of the stated research priority areas)
* Genetic Technologies:
* To advance the manipulation and modification of gene expression to alter the biological properties of living cells and tissues, with the goal of developing therapeutic solutions for inherited retinal diseases IRDs and dAMD.
* This funding opportunity seeks to advance viral and non-viral gene delivery systems, improve gene and RNA editing techniques, and develop scalable manufacturing processes that align with regulatory requirements for clinical translation.
* Restorative Therapies:
* To advance the development, regeneration, and application of human cells, tissues, and cellular/tissue-based products to restore retinal function and vision.
* The goal of this funding opportunity is to advance strategies that rescue or replace degenerating or dead retinal cells, optimize visual prostheses, and develop optogenetic approaches that confer light sensitivity to neuronal cells in the absence of functional photoreceptors.

Note: Research and technologies outside the scope of these areas may be considered with adequate preliminary data and justification.

Eligibility

_We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's [website]().
_

Application Details

Foundation Fighting Blindness
Brint Family Translational Research Program
Overview of Funding Opportunity
Request for Applications (Fiscal Year 2026 Cycle)
SUBMISSION AND REVIEW DATES AND TIMES
Request for Applications Release Date April 25, 2025
Proposers Day May 12, 2025; 11-12PM ET
Letter of Intent Due Date June 12, 2025
Full Application Invites August 18, 2025
Application Due Date October 16, 2025
Review of Applications October 2025 – March 2026
Anticipated Award Date March 2026
Table of Contents (hold Ctrl and click any item to jump to that section)
PROGRAM OVERVIEW .............................................................................................. 2
PROGRAM OBJECTIVES ........................................................................................... 4
Application Process Overview ..................................................................................... 9
Eligibility Criteria .......................................................................................................... 11
Letter of Intent Guidelines .......................................................................................... 13
Full Application Guidelines ......................................................................................... 14
Review Process and Evaluation Criteria .................................................................. 21
Non-Responsiveness Criteria .................................................................................... 22
Additional Resources .................................................................................................. 22
APPENDICES ............................................................................................................. 22

PROGRAM OVERVIEW:
Brint Family Translational Research Program (BFTRP) Funding Opportunity
Purpose:
BFTRP is the Foundation’s funding initiative aimed at accelerating preclinical
translational research for inherited retinal degenerations (IRD) and dry age-
related macular degeneration (dAMD). The program provides funding and
strategic guidance to advance novel therapies from the laboratory toward clinical
application (e.g., follow-on funding, FDA investigational new drug [IND] filing,
clinical trials, etc.). By leveraging expert mentorship in drug development,
regulatory strategy, intellectual property, and commercialization engagement, the
BFTRP seeks to address the complexities and diversity of these retinal diseases,
increasing the number of viable treatment options for our community.
Please review this entire document before preparing your full application as the
information provided will help you correctly formulate your proposal to meet the
requirements of this RFA.
Impact Expectations and Alignment with the Foundation’s Mission:
Applicants must ensure that their proposed research project aligns with the
Foundation’s mission to drive treatments and cures for IRDs and dAMD. Projects
should demonstrate a clear path toward clinical utility, with the goal of benefiting
the low-vision patient community. The Foundation emphasizes that applicants
should prioritize patient needs and consider the potential impact of their research
on improving patient outcomes throughout the research process.
The proposal should present an integrative approach to research and develop
and efficiently translate laboratory research findings into IND or investigational
device exemption (IDE) applications to regulatory agencies for testing new
therapeutic approaches.
This program does not solely support basic science, platform
technologies, or isolated technology development. Instead, the goal is to
generate preclinical data that will support a regulatory application (if applicable),
ensuring that each project has a well-defined endpoint of developing a new
therapy or device within a three-year timeframe. The steps toward this goal must
be clearly delineated through milestones.
pg. 2

Funding Information:
• The budget limit for this award is $1 million dollars distributed over a 3-year
period.
• The Foundation aims to catalyze translational efforts (lead optimization R&D
to IND-Enabling Studies) to accelerate discoveries and bring innovative
therapies closer to patients. Researchers and institutions are encouraged to
submit their applications, emphasizing rigorous scientific merit, feasibility, and
potential impact.
• It is anticipated that the Foundation will make between five to seven awards
for the FY2026 application cycle.
• The following are the allowable costs that should be reflected in the budget:
Personnel
o
Supplies (i.e., chemicals, reagents, tissue culture, etc.)
o
Travel Costs
o
Animal Costs
o
Patient Costs (itemized)
o
• The following are unallowable costs:
Facilities and Administrative Costs (also referred to as Indirect Costs)
o
These costs refer to the indirect costs that are incurred by an organization
o
to support its research activities but are not directly attributable to a
specific project.
Examples include, but are not limited to, (1) administrative support, (2)
o
building and facility maintenance, (3) library services, (4) general office
supplies, (5) institutional support services, (6) depreciation of research
equipment and facilities.
NOTE: Capital equipment is defined as permanent or semi-permanent
apparatus, devices or systems costing more than $5,000 per item or system.
Applicants must obtain prior approval from the Foundation to submit an
application proposing to purchase equipment. Contact the Foundation’s Senior
Director, Preclinical Translational Research Program for prior approval (email:
cjackson@fightingblindness.org). In addition, if approval is granted to submit a
request, all such equipment purchase requests must be well justified in the
budget section of the application and in the description of proposed project.
pg. 3

PROGRAM OBJECTIVES:
BFTRP Funding Opportunity Goal(s):
1. Advance Preclinical Research Toward Clinical Translation: BFTRP
supports high-impact translational research that moves promising IRD and
dAMD therapies from preclinical discovery through IND-Enabling studies to
regulatory engagement, accelerating their path to clinical application.
2. Develop Next-Generation Gene and Drug-Based Therapies: The program
funds research in gene therapy, RNA-based approaches, small molecules,
biologics, cell therapies, and restorative therapeutics (e.g., optogenetics,
prosthetics, etc.), to name a few, with an emphasis on improving efficacy,
delivery methods, and safety profiles.
3. Advance IND-Enabling and Clinical Readiness Studies: BFTRP supports
projects that generate preclinical data necessary for regulatory approval,
guiding researchers toward, the next developmental step and/or
investigational new drug (IND) filings, first-in-human trials, and
commercialization.
4. Overcome Key Translational Barriers in Retinal Disease Research: By
providing strategic funding and expert mentorship, the program helps
investigators navigate regulatory challenges, intellectual property
considerations, and therapeutic scalability, facilitating real-world impact.
5. Foster Multidisciplinary Collaboration for Innovation: Recognizing the
complexity of retinal degenerations, the program encourages cross-
disciplinary efforts, integrating genetic technologies, regenerative medicine,
bioengineering, and artificial intelligence to drive novel therapeutic strategies.
Preclinical Research Stages Eligible for Funding (Must be identified in
application)
• Early Preclinical Research – Lead Optimization:
Lead Optimization: Chemical modifications (for small molecules) or
o
vector engineering (for gene therapies) are performed to improve
efficacy, safety, and bioavailability of retinal therapy.
Early toxicology screenings, assessing off-target effects in cell-based
o
assays and initial small-animal models (e.g., zebrafish, rodents, etc.).
Studies that include blood-retinal barrier penetration, drug half-life, and
o
mechanisms of action in disease-relevant pathways (e.g., complement
system inhibition in dry AMD).
pg. 4

• Mid-Stage Preclinical Research – Proof of Concept in Animal or
Acceptable Regulatory Models (e.g., retinal organoids):
The best-performing therapeutic candidates are evaluated in relevant
o
animal models that mimic human retinal diseases.
Efficacy Studies: Gene therapies are delivered using AAV, lentivirus, or
o
nanoparticles, and their ability to restore photoreceptor or RPE function is
evaluated.
Small molecules are assessed for target engagement, disease
o
modification, and biomarker response in retinal degeneration models.
Pharmacokinetics (PK) and Pharmacodynamics (PD): Dose-response
o
relationships and retinal distribution are assessed to determine optimal
dosing strategies. Studies evaluate the duration of therapeutic effect,
including sustained release formulations for topical, intravitreal,
subretinal, subchoroidal, etc. injections.
Safety & Early Toxicology: Off-target effects and toxicity in ocular
o
tissues, as well as systemic exposure, are assessed in animal models.
If applicable, immune responses to gene therapy vectors (e.g., AAV
o
neutralizing antibodies) are evaluated.
• Late-Stage Preclinical Research – IND-Enabling Studies and Regulatory
Safety Studies to meet FDA standards:
GLP-Compliant Toxicology Studies: Long-term ocular and systemic
o
toxicity studies in two species (typically rodents + non-human primates)
to evaluate immune responses, inflammation, and dose-limiting toxicity.
Chronic exposure studies assess retinal structure (e.g., via OCT imaging)
o
and functional endpoints (e.g., ERG recordings).
Manufacturing & Scalability: Good Manufacturing Practice (GMP)
o
production is established for clinical-grade materials, including vector
batch production for gene therapies.
Drug formulation, stability, and shelf-life studies ensure clinical readiness.
o
Regulatory Readiness: Data from pharmacology, toxicology, and
o
efficacy studies.
Engagement with FDA, EMA, and other regulatory agencies helps define
o
clinical trial design and endpoints.
If possible, the Foundation highly encourages applicants include a plan to submit
or obtain an IND/IDE application, licensing effort, or transition their technology
toward clinical implementation within the award period. The specific activities
pg. 5

appropriate for the BFTRP phase will depend on the therapeutic or device under
study and the available preliminary data.
Research Priority Areas: The BFTRP delineates three (3) of the six (6)
Foundation research priority areas to guide funding toward preclinical projects
with the highest potential to advance the development of treatment of IRDs and
dAMD:
• Genetic Technologies:
Objective: To advance the manipulation and modification of gene
o
expression to alter the biological properties of living cells and tissues, with
the goal of developing therapeutic solutions for inherited retinal diseases
IRDs and dAMD. This funding opportunity seeks to advance viral and non-
viral gene delivery systems, improve gene and RNA editing techniques, and
develop scalable manufacturing processes that align with regulatory
requirements for clinical translation.
Key areas of interest include, but are not limited to:
o
 Enhancing Gene Therapy Delivery Methods: Improve and advance
delivery strategies by overcoming challenges associated with subretinal,
intravitreal, and suprachoroidal injections through the development of
clinically-relevant tools and solutions.
 Optimizing Retinal Cell Transduction: Develop and refine tools—such
as plasmids with cell type–specific promoters, novel viral capsids, or
nanoparticles—that enable efficient and targeted gene delivery to all
relevant retinal cell types, while also improving control over gene
expression levels.
 Delivery of Complex Genetic Constructs: Implement strategies for
delivering large DNA sequences, gene editing tools, mRNA, or proteins
to targeted retinal cells.
 Advancing RNA Editing Techniques: Develop and refine RNA editing
technologies to provide precise therapeutic modifications for IRDs and
dAMD.
 Establishing Quantifiable Delivery Metrics: Define metrics to measure
and quantify the efficiency of both viral and non-viral gene delivery, as
well as DNA/RNA editing, and demonstrate restoration of retinal function
and vision.
 Scalable and Affordable Manufacturing Techniques: Develop cost-
effective and scalable manufacturing processes that adhere to regulatory
requirements for clinical application.
pg. 6

 Exploring Novel Gene Therapy Platforms: Advance research in
plasmid or naked DNA, viral vectors, bacterial vectors, human gene
editing technologies, patient-derived cellular gene therapy products, and
innovative viral and non-viral gene delivery systems.
Key areas of interest must emphasize the advancement of therapeutic
approaches with a clear trajectory toward clinical application. Proposals
that focus solely on research without a defined plan for clinical relevance
or therapeutic translation will be less competitive during the review
process.
• Novel Medical Therapies:
Objective: The primary goal of this research priority area is to advance the
o
development of therapies that enhance or retain retinal function and
structure by optimizing drug efficacy, improving targeted delivery, and
minimizing toxicity. Therapeutic categories include (1) Small Molecules, (2)
Biologics, and (3) Alternative Therapies (research that falls outside of the
stated research priority areas).
Key areas of interest include, but are not limited to:
o
 Enhancing Retinal Cellular Metabolism & Neuroprotection: Advance
therapies that enhance cellular metabolism in the diseased retina and
demonstrating neuroprotective effects and/or stabilization or restoration
of retinal function.
 Overcoming Challenges in Therapy Development for Complex
Genetic IRDs: Address barriers in developing therapies for genetically
complex IRDs, including optimizing delivery systems to enhance efficacy
and reduce retinal toxicity.
 Gut Microbiome as a Therapeutic Target: Develop and evaluate
therapeutic interventions that modulate the gut microbiome to alter the
progression of IRDs and dAMD. Proposed strategies may include the use
of antibiotics, defined bacterial consortia, or fecal microbiota
transplantation. Projects should prioritize translational approaches with
clear therapeutic endpoints and may explore systemic, immune, or
metabolic pathways through which the gut microbiome influences ocular
health and disease.
 Non-Drug Therapeutic Approaches: Advance alternative therapeutic
strategies, such as red-light therapy, for IRDs and dAMD.
pg. 7

 Non-Invasive Drug Delivery Modalities: Advance non-invasive drug
delivery systems (e.g., topical or systemic administration) that are
particularly effective in early-stage disease intervention.
Key areas of interest must emphasize the advancement of therapeutic
approaches with a clear trajectory toward clinical application. Proposals
that focus solely on research without a defined plan for clinical relevance
or therapeutic translation will be less competitive during the review
process.
• Restorative Therapies (includes cell-based approaches, visual prosthetics
and optogenetics):
Objective: To advance the development, regeneration, and application of
o
human cells, tissues, and cellular/tissue-based products to restore retinal
function and vision. The goal of this funding opportunity is to advance
strategies that rescue or replace degenerating or dead retinal cells,
optimize visual prostheses, and develop optogenetic approaches that
confer light sensitivity to neuronal cells in the absence of functional
photoreceptors.
Key areas of interest include, but are not limited to:
o
 Cell Transplantation Optimization: Identify optimal preparation and
purification methods for donor tissue, enhance cell survival and function
post-transplantation, and establish effective immune suppression
regimens.
 Endogenous retinal regeneration and/or reprogramming: Develop
and advance therapeutic strategies that activate or enhance the eye’s
intrinsic capacity to repair or regenerate retinal cells affected by IRDs and
dAMD. Approaches may include reprogramming of resident retinal cells,
stimulation of Müller glia or other endogenous cell types, or modulation of
signaling pathways to promote cell survival, repair, or regeneration.
 Biomaterials & Transplant Integration: Biomaterials transplantation of
donor retinal pigment epithelium (RPE) and photoreceptors post-
transplantation and evaluate the transplant survival and retinal function
restoration.
 Optogenetic Approaches for Vision Restoration: Identify and target
the most effective retinal cells for optogenetic interventions that restore
vision.
pg. 8

 Visual Prostheses Development & Integration: Advance the design
and application of visual prostheses that interact effectively with
remaining retinal cells and neural circuitry to restore vision.
 Stem Cell Therapies & Retinal Organoids: Develop and apply stem
cell-based approaches, retinal organoids, and innovative cell delivery
systems (combination products) to enhance retinal repair and function.
Key areas of interest must emphasize the advancement of therapeutic
approaches with a clear trajectory toward clinical application. Proposals
that focus solely on research without a defined plan for clinical relevance
or therapeutic translation will be less competitive during the review
process.
Animal, Recombinant DNA and Human Subject Assurances:
• The Foundation, like the National Institutes of Health (NIH), uses the "Just in
Time" concept. Applicants may defer, until after completion of peer review and
just prior to funding: certification of Institutional Review Board (IRB) and
Institutional Biosafety Committee (IBC) approval of the application’s proposed
use of human subjects and proposed use of recombinant DNA; verification of
Institutional Animal Care and Use Committee (IACUC) approval of the
proposed use of live vertebrate animals; Health Insurance Portability and
Accountability Act (HIPAA) compliance; and, evidence of compliance with the
requirement for education in the protection of human research participants.
• Evidence of IRB, IACUC, and IBC approval must be documented by
submission of a signed the Foundation Institutional Agreement Form (IAF) at
the time of award. If approvals are pending at the time of award, the
Foundation funding cannot be expended for research involving human
subjects, recombinant DNA, and live vertebrate animals until the signed the
Foundation IAF is submitted to document that the appropriate approvals have
been obtained.
Examples of previously funding preclinical translational awards are listed
here:
• Foundation Funded Grants FY2024
Application Process Overview:
• Announcement of the Funding Opportunity: The process begins with the
publication of a Request for Applications (RFA) to solicit proposals for specific
pg. 9

scientific research areas aligned with the Foundation's mission. This RFA
details the objectives, eligibility criteria, submission guidelines, and evaluation
criteria. The Foundation strives to inform all relevant stakeholders and
potential applicants of this funding opportunity.
• Submission of Letter of Intent (LOI): Applicants are required to submit a
LOI by a specified deadline (June 12, 2025). The LOI serves as an initial
proposal overview and allows the Foundation to assess whether the proposed
research aligns with the Foundation's mission and priorities. This step is
required in order to be invited to submit a full application.
• Screening and Evaluation of LOIs: Upon receiving the LOIs, the Foundation’s
Scientific Advisory Board evaluates each submission. Applicants are notified if
their application will move forward in the application cycle, and top-scoring
applicants are invited to submit a full application (Due Date: August 18,
2025). This invitation is based on the LOI’s scientific merit, feasibility, and
alignment of the project with the Foundation’s priorities.
• Submission of Full Application (Due Date: October 16, 2025): Invited
applicants must submit a full, detailed application that expands on the
information provided in the LOI. This includes a comprehensive research plan,
detailed budget, timeline, and additional supporting materials such as
biosketches, letters of support, and institutional endorsements.
• Comprehensive Review of Full Applications: The full applications are then
subjected to a more in-depth evaluation process by the Foundation’s Science
Advisory Board. Three research priority area committees review the
applications: (1) Novel Medical Therapy, (2) Genetic Technologies, and (3)
Restorative Therapies.
• Funding Decision: The final funding decision is made by the Foundation’s
Executive Science Advisory Board and Board of Directors informed by the
committee’s review. A formal award notification is issued to the successful
applicants, and funding agreements are negotiated and finalized.
Through this process, the Foundation ensures that only the most competitive and
relevant research and development plans receive funding, and that each
research project has the potential to make a meaningful impact in advancing
scientific understanding or clinical solutions for IRD and dAMD therapeutics.
A Proposer’s Day will be held on May 12, 2025, from 11-12PM ET, via ZOOM to
review the program and answer questions (Register Here).
pg. 10

Email questions to the Senior Director, Preclinical Translational Research
Program at cjackson@fightingblindness.org.
Eligibility Criteria
• Proposed BFTRP research must meet the following criteria:
Proposals exploring therapeutic solutions for IRDs should focus on retinal
o
degenerations with clear genetic disease drivers (e.g., ABCA4 disease)
and/or take an agnostic approach to addressing IRDs.
The applicant MUST identify one of the three Research Priority Areas listed
o
as the approach taken to provide a new IRD or dAMD therapy. However, if
outside the scope of the listed Research Priority Areas include as a part of
the Novel Medical Therapies and indicate in the proposal and provide
adequate background and/or preliminary results to justify funding.
Research should be hypothesis driven; however, it is not required if a
o
proposal demonstrates that the project has already identified a target,
developed a lead therapeutic, and shows a plan toward optimization and
development of a product for clinical use.
Clearly state how the proposed research project is geared toward
o
developing a product to address inherited retinal degenerations and/or dry
age-related macular degeneration and has the potential advance to the
next stage of development (e.g., IND filing, venture capital, etc.).
Must use functional efficacy models/assays that are appropriate and
o
relevant to regulatory (FDA, EMA, etc.) filing.
Applicants should demonstrate how their technology will potentially work in
o
the clinic. Also, include statement on marketplace impact as compared to
current practices. Consider including a Target Product Profile table to
highlight.
Applicants should provide an intellectual property (IP) and/or protection
o
strategy for their technology.
• BFTRP applicants must meet the following criteria:
Applicants must hold a research leadership position (e.g., faculty position,
o
director of research, etc.) at an accredited academic medical center,
university, research institution, or company who can independently conduct
research with full support of their organization.
pg. 11

If you are applying as a company, please directly contact the Senior
o
Director of the Preclinical Translational Research Program
(cjackson@fighitngblindness.org). There are additional considerations
that will need to be discussed before a full application is submitted.
A project shall have only a single Principal Investigator (PI; or single
o
Program Director for a PPA), who is responsible for project oversight,
fiscal management, and reporting. The PI may engage collaborators,
core labs or commercial CROs to execute any fraction of the project if it
adheres to the awarded budget.
Applicants must fully demonstrate all research and development
o
personnel have the skillsets to execute proposed work.
Applicants must show that the location(s) where the work is to be
o
conducted has adequate space, equipment, tools, protocols, safety, and
regulatory measures to execute research.
Any proposed research partnerships must be already established prior
o
to application submission. This will be made clear with written
confirmation provided to the Foundation at the time of the proposal, and
if applicable, a proposed cost sharing agreement. NOTE: If working with
a CRO, please consider addressing the following:
 Project Management: Determine whether the project manager will be
an internal team member or provided by the CRO. A dedicated
project manager enhances communication and oversight, ensuring
project milestones are met.
 Data Management: Clarify how data accuracy, confidentiality, and
security will be maintained. Ensure the CRO has robust data
management systems and a history of compliance with data handling
standards.
 Contractual Agreements: Negotiate contracts that include clear
milestones, confidentiality clauses, and payment terms. Consider
structures where the CRO shares some project risks, aligning their
incentives with project success.
 Vendor Qualification: Provide cost estimates from potential
CROs/Contract Manufacturing Organizations (CMOs) during the
application process. Post-selection verifies these estimates and
assesses the CRO's qualifications to ensure they meet regulatory
requirements and have relevant experience.
 Regulatory Compliance: If considering international CROs/CMOs,
ensure they comply with U.S. State Department regulations and NIH
pg. 12

policies. Be aware that using international vendors may require
additional clearances and could delay project initiation.
Letter of Intent Guidelines
• The Letter of Intent is required prior to being invited to submit a full
application.
• Only two (2) LOIs can be submitted per person, laboratory, company.
• Applicants shall submit their LOI information through the JUMP application
portal: (https://www.onlineapplicationportal.com/blindness)
• LOI Due Date: June 12, 2025 (Close of Business, Eastern Standard Time).
• Please include in the LOI submission:
Project Title
o
Identify Research Priority Area (1. Genetic Technologies; 2. Novel Medical
o
Therapies; 3. Restorative Therapeutics – Must Select One)
Project Abstract/Summary (600-word limit): It is recommended that the
o
specific aims are listed, and rationale stated. Use the Overall Application
Description section below to elaborate on the research plan and scientific
approach.
Overall Application Description (1200-word limit):
o
 Describe the research plan.
 Include a brief statement that describes the research project’s preclinical
stage of development (e.g., Early Preclinical; 2. Mid-Stage Preclinical; 3.
Late Stage Preclinical – the definitions of each stage can be found on
pages 4 and 5 of this RFA).
 Applicants MUST include a clear statement outlining the key scientific
milestones that will define success for the proposed project. In addition,
please describe the logical next steps for the research or technology if
this funding results in positive outcomes. This should include potential
follow-on funding sources that may be pursued to advance the future
therapeutic.
 We also encourage applicants to provide a forward-looking roadmap
that outlines the regulatory and commercialization pathway, if
applicable. This may include steps such as Investigational New Drug
(IND) application planning, regulatory consultations, clinical trial
readiness, or strategies for partnering and market entry.
 Discuss the potential project challenges and risk mitigation strategies.
pg. 13

 Summarize the potential translational impact (e.g., how this leads to a
therapy for IRD or dry AMD).
 If supporting figures and references are to be included as an appendix,
a maximum of 3 figures or tables can be uploaded separately to the
Figures Upload page. Include Reference list in this field (please keep as
brief as possible).
 Names of Key Personnel, Collaborators, and Institutions
 Cost and Timeline (budget categories are outlined in the Resource
Download section: Application Instructions – Brint Family Translational
Research Program Award).
 Principal Investigator’s Curriculum Vitae
• LOI Formatting Instructions:
Use an Arial typeface and a font size of 11 points or larger. (A Symbol font
o
may be used to insert Greek letters or special characters; the font size
requirement still applies.).
Use a 1” margin.
o
Type density, including characters and spaces, must not exceed 15
o
characters per inch.
Type may be no more than six lines per inch.
o
All limits specified refer to single-spaced format using the above formatting
o
requirements.
• LOI Due Date: June 12, 2025 (Close of Business, Eastern Standard Time).
Full Application Guidelines
All applications must have been invited to submit full applications. Full
applications must be submitted online. If attachments are required, they also
must be submitted through the application portal.
NOTE: The complete full application must be SUBMITTED by 11:59PM (EST)
OCTOBER 16, 2025, or will not be included in the application review cycle.
How to begin online submission:
pg. 14

• First create an account on the site’s homepage
(blindness@onlineapplicationportal.com) by selecting “Applicant Registration-
start here” underneath the Foundation logo. If you have previously created an
account, this step is not necessary.
• You may log out and return to your application in-progress as many times as
you wish until it has been submitted. To be considered for the award, your
online application must be complete and in SUBMITTED status no later than
11:59 PM EST October 16, 2025.
• How to enter information:
You may begin completing the application in any section. To begin, choose
o
a section of the application from the left menu or click "Continue" at the
bottom of the screen.
Text boxes will allow the allotted amount of text as specified in the
o
submission instructions. Where longer answers are permitted, the number
of available characters will be indicated. Before submitting, we suggest you
print and examine a hard copy of your application to be certain your
responses are complete and accurate.
The information you provide will be saved exactly as entered. Therefore, fill
o
out the form carefully, paying attention to spelling, case (do not use all
caps), punctuation, et cetera, and give special consideration when entering
your contact information.
Begin typing all answers at the extreme left-hand side of the response area
o
or box; do not leave a space or indent at the beginning of your answer.
• How to SAVE and SUBMIT your data:
You must SAVE each time you leave a screen. If you do not click on SAVE
o
or SAVE & CONTINUE, anything entered since you last hit SAVE on that
screen will be lost (any work from a previous session will be retained, but
any new entries will be lost). The SAVE and SAVE & CONTINUE buttons
are at the bottom of your screen.
You may work on your application over as many sessions as you wish, and
o
the status of your application will be IN PROGRESS until you submit it.
Once you are satisfied that your application is complete, you must go to the
"Submit Application" screen and select SUBMIT APPLICATION.
If for some reason you need to make changes after your application is
o
submitted, email blindness@onlineapplicationportal.com.
Information on your application status may be found on the Online
o
Application Portal home page.
pg. 15

• BFTRP Application Components:
Use an Arial typeface and a font size of 11 points or larger. (A Symbol font
o
may be used to insert Greek letters or special characters; the font size
requirement still applies.)
Use a 1” margin.
o
Type density, including characters and spaces, must not exceed 15
o
characters per inch.
Type may be no more than six lines per inch.
o
All page limits specified refer to single-spaced format using the above
o
formatting requirements.
 ABSTRACT: up to 1-single-spaced page
 SPECIFIC AIMS/RATIONALE: up to 2 single-spaced pages
 PRELIMINARY/SUPPORTING DATA: up to 2 single-spaced pages.
 DETAILED PROJECT DESCRIPTION (Includes Experimental Plan and
Methods): up to 9 single-spaced pages.
 KEY PERSONNEL: Up to 1 single-spaced page per person.
 MANAGEMENT PLAN: Up to 1 single-spaced page
 BUDGET and BUDGET JUSTIFICATION: up to 2 single-spaced pages
• Application Face Page:
The Face Page of the application must be signed by both the Principal
o
Investigator and an authorized institutional official who is legally permitted
to sign on behalf of the applicant institution. Before submitting the
application, applicants must print the completed Face Page, obtain the
required signatures, and upload the signed document to the designated
Face Page Upload section of the application portal. Applications submitted
without the appropriate signatures will be considered incomplete.
• Abstract (limit: 1 single-spaced page, see Application Formatting Instructions)
Provide an abstract of the proposed research project, written in lay terms
o
for a non- scientific audience. The abstract should contain non-confidential
material that can be posted on Foundation’s web site if the application is
funded.
 Include the following in the abstract:
The research question(s) to be investigated and/or will lead an
o
advancement to the next stage of preclinical development.
The significance of the proposed project in terms of accelerating the
o
advancement of therapeutic and preventive approaches for IRDs and
dAMD into the clinic, and how the proposed research directly
supports the mission of the Foundation.
pg. 16

A brief lay description of all specific aims, including experimental
o
approaches, and a listing of all diseases/patient populations to be
studied.
The expected accomplishments and outcomes for each specific aim.
o
• Specific Aims and Rationale (limit: 1-2 single-spaced pages, see Application
Guidelines and Components):
 Describe the overall goal(s) and rationale for the proposed project.
Numerically list the specific aims and describe the anticipated results to
be achieved in each year of the project. Note that successful applicants
will be required to participate in monthly technical update meetings (with
meeting materials [e.g., PowerPoint slides]) and submit Annual Progress
Reports that detail accomplishments for each of the specific aims
identified in the application.
 Describe the potential clinical value of the proposed research in terms of
developing therapeutic and preventive interventions for IRDs and dAMD,
including the feasibility of applying the anticipated results to the
development of new or improved interventions.
 Briefly discuss how you envision the Foundation’s funding of this
proposed research to promote, supplement, or complement future
support from the NIH and/or other funding agencies, organizations,
private companies, etc.
• Preliminary and Supporting Data (limit: 2 single-spaced pages, see
Application Guidelines and Components):
 Describe existing experimental data or prior clinical research that
support(s) the soundness and feasibility of the proposed experiments.
Include evidence of in vitro and/or in vivo experiments, if applicable, that
demonstrate the relevance of the proposed experiments for advancing
therapeutic and preventive interventions
• Detailed Project Description (limit: 9 single-spaced pages, see Application
Guidelines and Components):
Experimental Plan and Methods: (limit: 5 single-spaced pages, see
o
Application Guidelines and Components)
 For each specific aim, describe the experimental design, procedures,
and methods to be used. The level of detail in a NIH investigator-
initiated research project Award application is not required by the
Foundation. However, applicants must include sufficient information so
that reviewers can understand the proposed experiment, its soundness,
pg. 17

feasibility, and importance for advancing a therapeutic strategy for IRDs
and dAMD.
 Applications proposing research using human samples must provide the
information delineated below.
 NOTE: If IRB approval is not required to conduct the proposed clinical
study using human samples, then such projects are considered non-
clinical, and applicants are not required to provide the
information/materials listed below.
Clinical Research Requirements (if applicable):
o
 Study Description: A description of the proposed clinical
study, including: (a) hypothesis and study objectives; (b) study
population(s) and relevance of the proposed study to clinical
disease/patient outcome; (c) study design, methodologies, and
the scientific rationale, including supporting data from
completed basic, preclinical and clinical research, and the
feasibility and appropriateness of applying such supporting data
to the design and execution of the proposed clinical study; (d)
statistical analysis plan; and, (f) plan for receipt and storage of
human samples.
 Human Samples: Documentation of the ability to acquire
human samples prospectively or retrospectively, including
obtaining samples from planned, ongoing or completed clinical
studies/trials sponsored by any source. This should include
written agreements between the applicant institution, the clinical
trial sponsor, and the Investigational New Drug (IND) or
Investigational Device Exemption (IDE) sponsor, if not one of
the above, for the conduct of the proposed study.
 Informed Consent: A copy of the approved or proposed
informed consent form to be used for collection of patient
samples (include in Appendix Materials, Reprint Section; does
not count against 9-page proposal limit).
• Milestones and Timelines: A clear delineation of SMART milestones
(Specific, Measurable, Achievable, Relevant, and Time-bound) is a critical
aspect of this program.
Each application must propose a well-defined series of milestones,
o
including key experiments, manufacturing (if applicable) and product
development objectives. Applicants are strongly encouraged to include
pg. 18

contingency plans to proactively address potential delays in meeting these
milestones.
Prior to awarding funding, program staff will collaborate with the applicant
o
to refine and finalize the proposed milestones. These agreed-upon
milestones will be incorporated into the terms and conditions of the award
and will serve as the basis for evaluating project progress.
Please consider using a Gnatt chart when formulating this information for
o
the application.
• Collaborative Plan: Include plans for collaboration with other investigators to
share research materials, methodologies/technologies, animal models, patient
assessment tools and results, and both positive and negative findings.
• Future Relevance: If the aims of the application are achieved, describe how
scientific knowledge or clinical practice will be advanced. Include a brief
discussion on the anticipated effect of the study on the concepts, methods,
technologies, treatments, services, or preventive interventions that drive the
field of research on inherited retinal degenerative diseases and dry age-
related macular degeneration.
• Technology Protection and Transition Plan: During the project, it is
possible that new intellectual property (IP) may be developed. Applicants must
provide a detailed plan outlining how any IP generated during the funding
period will be protected. In addition, one of the goals of this program is to
advance research to the next stage of development, which may include
technology transition activities such as licensing, forming a startup (newco), or
other commercialization efforts. Please describe any past, current, or planned
efforts related to the transition or commercialization of the proposed
technology included in this application.
• References: Provide a list of references and abstracts for: (a) publications
relevant to the data cited to support the science for the proposed research;
and (b) up to five pertinent reprints representing the applicant’s research.
Copies of the reprints can be uploaded on the REPRINT page. This
information does not count against the page limits for the Detailed Project
Description.
• Key Personnel:
Each Individual Investigator Research Award Application must be directed
o
by a single Principal Investigator who is responsible for the conduct and
management of the project. Co-Investigators are allowed and must be
identified.
pg. 19

Add all key scientific and technical personnel involved in the proposed
o
project. Designate researchers who are co-investigators.
Provide current and pending sources of ALL research support. For each
o
source (federal, private, or commercial) provide (a) title, (b) grant number,
(c) percent effort, (d) funding amount, and (e) budget period. This
information should include total support for all current and proposed
projects.
Provide abbreviated CVs (5-page limit) for all key personnel (NIH biosketch
o
is acceptable), listing ONLY RELEVANT publications from the last three
years and representative publications prior to that. DO NOT include
Abstracts.
• Management Plan (limit: 1 page): All awarded projects must present a
management plan that details the activities of all key scientific and technical
personnel involved in the proposed project. The PI and the Senior Director of
the Preclinical Translational Research Program at the Foundation Fighting
Blindness will hold monthly progress meetings to:
Track the technical progress of the project.
o
Reports and briefing material will also be required as appropriate to
o
document progress in accomplishing project metrics and milestones – a
PowerPoint template will be provided.
This meeting will also provide an opportunity to address any program
o
delays or potential rescoping ideas.
• Budget (limit: 1-2 pages): For each year of support requested, provide a
detailed, itemized budget and budget justification for each of the categories
listed below:
Personnel: Listed by name with percent effort, salary, and fringe benefits
o
requested. Salary Support for the Principal Investigator of up to twenty (20)
percent of the total annual budget is permitted. There is no salary cap.
Supplies: (Itemized by category, e.g., glassware, molecular biology
o
reagents, not by individual items within the category).
Patient Costs: (Itemized)
o
Animal Costs: (Itemized)
o
Travel Costs: (limits): $2,000 per annum (U.S., Canada), $2,500 per annum
o
(Europe), $3,000 per annum (e.g., South America, Australasia, India,
Japan, China), $2000 will be added to the budget for travel to the
Program’s Biennial In-Person meeting.
Other Costs: (Itemized).
o
pg. 20